Pushing the limits of brain imaging: A new tool for targeted delivery of imaging agents and drugs

Pushing the limits of brain imaging: A new tool for targeted delivery of imaging agents and drugs

Multiphoton microscopy is a valuable tool for neuroscience research, allowing scientists to observe functional brain activity in real time through high-resolution imaging. An essential component of many multiphoton microscopy imaging studies is the delivery of chemical compounds, including imaging agents and drugs. However, many compounds cannot cross the blood-brain barrier and, therefore, cannot be delivered to the brain through systemic admin…

Biogen, Genentech Set for June Trial Over MS Drug Royalties

Biogen Inc. and Genentech Inc. are heading to trial in June over a significant contract dispute concerning patent royalties on multiple sclerosis (MS) drug sales. A federal judge in California recently denied Biogen’s motion for summary judgment, signaling that the case will proceed to trial. The lawsuit, originally filed by Genentech in February 2023, centers around a breach of contract regarding the royalties owed by Biogen for the MS drug, Ty…

AAN 2025: CAR T-cell therapy shows safety, efficacy in 2 MS trials

Kyverna Therapeutics’ CAR T-cell therapy candidate KYV-101 was deemed safe and well tolerated, and showed preliminary signs of efficacy, in people with progressive forms of multiple sclerosis (MS) in clinical testing. That’s according to data from two investigator-initiated Phase 1 trials, which enrolled individuals with secondary progressive MS (SPMS) and primary progressive MS (PPMS) who […] The post AAN 2025: CAR T-cell therapy for MS shows s…

AAN 2025: PrimeC reduces miRNAs linked to ALS progression

Neurosense Therapeutics’ oral therapy PrimeC significantly reduces blood levels of miRNAs — molecules involved in regulating gene activity — associated with disease progression and survival in people with amyotrophic lateral sclerosis (ALS). That’s according to six-month biomarker data from the Phase 2b PARADIGM clinical trial (NCT05357950), in which 68 adults with ALS were randomly assigned to receive either PrimeC or a placebo for six months, …

Phase II Trial Shows Clinical and Imaging Evidence of Brain Repair in MS: AAN 2025

AAN 2025: Long-term data from the VISIONARY-MS Phase 2 trial links improved brain imaging and visual evoked potentials to remyelination and neuronal repair in MS patients treated with CNM-Au8.